ClinicalTrials.gg
RecruitingNCT05529459ASSISTUpdated Jan 10, 2025

Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD

An interventional study of Percutaneous Coronary Intervention in Coronary Disease, sponsored by Seung-Whan Lee, M.D., Ph.D.. Recruiting at 17 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by Seung-Whan Lee, M.D., Ph.D. · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,400
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Coronary Disease with a site in Korea, Republic of — 6 open to participants now, 7 under way, none of them phase 3. Coronary Disease · Korea, Republic of.

Planned enrollment
9th of 29
2,400 · median 1,000
Started
2023
the only one that year
No phase
7 of 49
2 open now
Registered
48th of 49
by date

Among the 49 studies in Coronary Disease with a site in Korea, Republic of, this one is the 9th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2023, is one of 7 with no phase, and was the 48th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

6 of the 49 studies in Coronary Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Coronary Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is to compare clinical outcomes between quantitative coronary angiography-guided anatomic complete revascularization and fractional flow reserve-guided physiologic complete revascularization in patients with significant coronary artery disease undergoing percutaneous coronary intervention with drug eluting stent

Read the detailed description

This is a prospective, multicenter center, open-label, randomized trial to compare QCA-guided versus FFR-guided CR strategies in patients with significant CAD who are undergoing PCI with DES. Patients with symptoms or evidence of myocardial ischemia are eligible for enrollment if there have stenotic lesions with a diameter stenosis of 50%-90% in major epicardial coronary arteries ≥ 2.25 mm in diameter by visual estimation, and CR is expected to be achievable by PCI. The detailed information for inclusion and exclusion criteria is described below in the session 4. Patients meeting inclusion criteria without any exclusion criteria will be randomized to either QCA-guided CR or FFR-guided CR group. In the QCA-guided CR group, PCI will be performed if there are lesions with diameter stenosis ≥ 50% by QCA during the index procedure (and, if necessary, planned staged procedure). In the FFR-guided CR group, FFR is measured for the target coronary lesions, and then PCI will be performed for the lesions with FFR ≤0.80. Post-PCI FFR measurement is strongly recommended. However, additional procedures are not recommended based on post-PCI FFR value because there is no consensus of the optimal cut-off value to define physiologic CR. In both QCA-guided and FFR-guided PCI groups, imaging guidance during PCI is left at the discretion of the operator. However, routine high pressure post-dilation with noncompliant balloons is recommended to achieve optimal stent expansion with minimal residual stenosis (diameter stenosis \< 10% on visual estimation). Patients will be followed clinically at 1, 6, 12 months, and then upto 5 years after the index procedure

03

Conditions studied

  • Coronary Disease

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women between the ages of 19and older
  • Typical chest pain or objective evidence of myocardial ischemia suitable for PCI Significant lesions with a diameter stenosis of 50-90% in major epicardial coronary arteries ≥ 2.25 mm in diameter by visual estimation.
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion criteria

Exclusion Criteria:

  • Coronary lesions resulting in the expected inability to perform FFR (ex, severe tortuosity or extreme angulation of the vessels)
  • Chronic total occlusion
  • Failed PCI of severe stenotic (diameter stenosis > 90%) or ACS culprit lesions
  • Previous PCI within 6 months before the index procedure
  • Previous coronary artery bypass graft surgery
  • Cardiogenic shock or hemodynamic instability
  • Left ventricular dysfunction ( \< 35%)
  • \< 1 years for any non-cardiac or cardiac causes
  • Any surgery requiring general anesthesia or discontinuation of aspirin and/or an ADP antagonist is planned within 12 months after the procedure
  • A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer
  • Patient's pregnant or breast-feeding or .
  • A known intolerance to antiplatelet agents (aspirin, clopidogrel, prasugrel or ticagrelor)
  • or to DES material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated
  • Any abnormality identified at the screening visit, physical examination, laboratory tests, or which, in the judgment of the investigator, would preclude safe completion of the study
  • Unwillingness or inability to comply with the procedures described in this protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
2,400 participants (estimated)

Study arms

  • Experimental
    quantitative coronary angiography-guided percutaneous coronary intervention

    Successful revascularization of all coronary artery lesions or segments ≥2.25 mm\* in diameter with ≥50% diameter stenosis by QCA regardless of their functional significance

    Procedure: Percutaneous Coronary Intervention

  • Active comparator
    fractional flow reserve-guided PCI

    Successful revascularization of all coronary artery lesions or segments ≥2.25 mm in diameter with evidence of ischemia or hemodynamic significance by FFR ≤ 0.80 regardless of their anatomic severity†

    Procedure: Percutaneous Coronary Intervention

Interventions

  • ProcedurePercutaneous Coronary Intervention

    Percutaneous Coronary Intervention

06

What researchers measure

Primary outcomes

  1. Number of Participants with death

    Major adverse cardiac events are defined as all-cause death

    Time frame: 12month

  2. Number of Participants with MI

    Non-fatal myocardial infarction includes both spontaneous MI and periprocedural MI.

    Time frame: 12month

  3. Number of Participants with unplanned repeat revascularization

    Unplanned repeat revascularization is defined as revascularization of any diseased coronary arteries ≥ 2.0 mm in diameter by QCA due to recurred angina with at least one of the following: (1) positive non-invasive test, (2) positive invasive physiologic test, or (3) presence of diameter stenosis ≥50% by QCA.

    Time frame: 12month

Secondary outcomes

  1. Number of Participants with death

    Major adverse cardiac events are defined as all-cause death

    Time frame: 5years

  2. Number of Participants with MI

    Non-fatal myocardial infarction includes both spontaneous MI and periprocedural MI.

    Time frame: 5years

  3. Number of Participants with unplanned repeat revascularization

    Unplanned repeat revascularization is defined as revascularization of any diseased coronary arteries ≥ 2.0 mm in diameter by QCA due to recurred angina with at least one of the following: (1) positive non-invasive test, (2) positive invasive physiologic test, or (3) presence of diameter stenosis ≥50% by QCA.

    Time frame: 5years

  4. Number of Participants with bleeding

    Major or minor bleeding according to definitions from TIMI

    Time frame: 5years

  5. Number of Participants with rehospitalization

    Rehospitalization for an acute coronary syndrome or repeat PCI

    Time frame: 5years

  6. Self-rated health on a vertical visual analogue scale by EQ5D

    EQ-5D is a standardized measure of health-related quality of life developed by the EuroQol Group and provides a simple and general questionnaire for use in clinical assessments

    Time frame: 5years

  7. cost-effectiveness

    Procedure-related cost during index procedure

    Time frame: 5years

07

Study locations

12 of 17 sites recruiting
  • Hallym University Sacred Heart Hospital
    Anyang, Korea, Republic of
    Not yet recruiting
    • Kyoung-Ha Park, MD · Contact
    • Yoon Seok Koh, MD · Principal investigator
  • Bucheon Sejong Hospital
    Bucheon, Korea, Republic of
    Not yet recruiting
    • Ha-Wook Park, MD · Contact
    • Ha-Wook Park, MD · Principal investigator
  • Inje University Busan Paik Hospital
    Busan, Korea, Republic of
    Recruiting
    • Tae-Hyun Yang, MD · Contact
    • Min Ku Chon, MD · Principal investigator
  • Gyeongsang National University Changwon Hospital
    Changwon, Korea, Republic of
    Recruiting
    • Jae Seok Bae, MD · Contactbaefach@naver.com
    • Jae Seok Bae, MD · Principal investigator
  • Chungbuk National University Hospital
    Cheongju, Korea, Republic of
    Recruiting
    • Sang Min Kim, MD · Contact
    • Sang Min Kim, MD · Principal investigator
  • Daegu Veterans Hospital
    Daegu, Korea, Republic of
    Recruiting
    • Jeong Hwan Cho, MD · Contact
    • Jeong Hwan Cho, MD · Principal investigator
  • Keimyung University Dongsan Medical Center
    Daegu, Korea, Republic of
    Recruiting
    • Hyuck Jun Yoon, MD · Contact
    • Hyuck Jun Yoon, MD · Principal investigator
  • Gangneung Asan Hospital
    Gangneung, Korea, Republic of
    Recruiting
    • Hanbit Park, MD · Contact
    • Hanbit Park, MD · Principal investigator
  • Wonkwang University Hospital
    Iksan, Korea, Republic of
    Recruiting
    • Jae Young Cho, MD · Contact
    • Jae Young Cho, MD · Principal investigator
  • Kwangju Christian Hospital
    Kwangju, Korea, Republic of
    Recruiting
    • Seung Uk Lee, MD · Contact
    • Seung Uk Lee, MD · Principal investigator
  • Inje University Pusan Paik Hospital
    Pusan, Korea, Republic of
    Recruiting
    • Tae Hyun Yang, MD · Contactyangthmd@naver.com
    • Tae Hyun Yang, MD · Principal investigator
  • Bundang CHA Hospital
    Seongnam, Korea, Republic of
    Not yet recruiting
    • Se Hun Kang, MD · Contact
    • Se Hun Kang, MD · Principal investigator
  • Asan Medical Center
    Seoul, Korea, Republic of
    Recruiting
    • Seung-Whan Lee, MD · Contactseungwlee@amc.seoul.kr
    • Seung-Whan Lee, MD · Principal investigator
    • Pil Hyung Lee, MD · Sub investigator
    • Tae Oh Kim, MD · Sub investigator
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Hyungjun Joo, MD · Contact
    • Hyungjun Joo, MD · Principal investigator
  • Veterans Hospital Service Medical Center
    Seoul, Korea, Republic of
    Recruiting
  • The Catholic University of Korea, ST. Vincent's Hospital
    Suwon, Korea, Republic of
    Not yet recruiting
    • Sung-Ho Her, MD · Contact
    • Sung-Ho Her, MD · Principal investigator
  • Pusan National University Yangsan Hospital
    Yangsan, Korea, Republic of
    Not yet recruiting
    • mingu chon, MD · Contact
    • mingu chon, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 45 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2022
First posted
Sep 7, 2022
StartActual
Mar 13, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 31, 2030
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05529459
Lead sponsor
Seung-Whan Lee, M.D., Ph.D.
Collaborators
Biotronik Korea Co., Ltd
Responsible party
Seung-Whan Lee, M.D., Ph.D. (Principal investigator, Asan Medical Center) — Sponsor-investigator
First posted
Sep 7, 2022
Start date
Mar 13, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Jan 10, 2025

Study contacts

Jiwon Baek, RN
Contact
cvcrc22@amc.seoul.kr
82230107267
Seung-Whan Lee, Investigator
Contact
seungwlee@amc.seoul.kr
82230103170
Seung-Whan Lee, Investigator
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion